Literature DB >> 322399

Treatment of Gram-negative bacillary meningitis with intrathecal gentamicin.

R J Mangi, L L Holstein, V T Andriole.   

Abstract

In order to evaluate the effect of intrathecal gentamicin on gram-negative bacillary meningitis, twenty-eight patients were treated with intralumbar or intraventricular gentamicin in combination with systemic gentamicin and with other antibiotics. Sterile cerebrospinal fluid was achieved in 21/22 (95%) episodes of documented gram-negative bacillary meningitis in patients who received more than one day of therapy. Seventy-seven percent of these patients survived their infection. The mean cerebrospinal fluid gentamicin level measured 24 hours after intrathecal administration was 5.9 ug/ml following intralumbar administration and 11.1 ug/ml following intraventricular administration. Toxic side effects due to intrathecal administration of gentamicin were not noted. These findings suggest that both intralumbar and intraventricular administration of gentamicin are safe and efficacious in the treatment of gram-negative bacillary meningitis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 322399      PMCID: PMC2595307     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  18 in total

1.  GENTAMICIN: ACTIVITY IN VITRO AND OBSERVATIONS IN 26 PATIENTS.

Authors:  J O KLEIN; T C EICKHOFF; M FINLAND
Journal:  Am J Med Sci       Date:  1964-11       Impact factor: 2.378

2.  Treatment of ventriculitis with gentamicin in an infant born with spina bifida.

Authors:  K van der Waarde; M van de Wiel-Korstanje
Journal:  Scand J Infect Dis       Date:  1972

3.  Intrathecal gentamicin in treatment of bacterial meningitis.

Authors:  J R Graybill; J Mann; P Charache
Journal:  Johns Hopkins Med J       Date:  1973-07

Review 4.  Treatment of gram-negative bacillary meningitis in adults.

Authors:  J J Rahal
Journal:  Ann Intern Med       Date:  1972-08       Impact factor: 25.391

5.  Treatment of ventriculitis with gentamicin and cloxacillin in infants born with spina bifida.

Authors:  J Lorber; S C Kalhan; B Mahgrefte
Journal:  Arch Dis Child       Date:  1970-04       Impact factor: 3.791

6.  Development of meningitis during cephalothin therapy.

Authors:  R J Mangi; R S Kundargi; R Quintiliani; V T Andriole
Journal:  Ann Intern Med       Date:  1973-03       Impact factor: 25.391

7.  Intrathecal gentamicin.

Authors:  J Smilack; R V McCloskey
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

8.  Gentamicin: in vitro studies.

Authors:  W M Kirby; H C Standiford
Journal:  J Infect Dis       Date:  1969 Apr-May       Impact factor: 5.226

9.  Gentamicin therapy of Paracolobactrum epidural abscess and meningitis.

Authors:  M Rubenfire; H H Gass; A S Goldstein; A M Lerner
Journal:  Am J Med Sci       Date:  1969-03       Impact factor: 2.378

10.  Combined intrathecal and intramuscular gentamicin for gram-negative meningitis. Pharmacologic study of 21 patients.

Authors:  J J Rahal; P J Hyams; M S Simberkoff; E Rubinstein
Journal:  N Engl J Med       Date:  1974-06-20       Impact factor: 91.245

View more
  2 in total

1.  CT and MR imaging features of pyogenic ventriculitis.

Authors:  M B Fukui; R L Williams; S Mudigonda
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

2.  Ventriculitis: A Severe Complication of Central Nervous System Infections.

Authors:  David Luque-Paz; Matthieu Revest; François Eugène; Sarrah Boukthir; Loren Dejoies; Pierre Tattevin; Pierre-Jean Le Reste
Journal:  Open Forum Infect Dis       Date:  2021-04-29       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.